5 High Growth Pharma Stocks that are Profitable

4. Vir Biotechnology, Inc. (NASDAQ:VIR)

Q/Q Sales Growth: 263%

Number of Hedge Fund Holders in Q3 2022: 18

Vir Biotechnology, Inc. (NASDAQ:VIR) develops several treatments for diseases such as the coronavirus, hepatitis, HIV, influenza, and other diseases. The firm is based in San Francisco, California.

Vir Biotechnology, Inc. (NASDAQ:VIR) earned $374.6 million in revenue for the three months that ended in September 2022. This enabled the firm to post a whopping 263% annual growth. Insider Monkey’s Q3 2022 survey covering 920 hedge funds revealed that 18 had invested in the company.

Vir Biotechnology, Inc. (NASDAQ:VIR)’s largest investor is Jim Simons’ Renaissance Technologies which owns 1 million shares that are worth $26 million.

Follow Vir Biotechnology Inc. (NASDAQ:VIR)